Parameter
| Biomarker | OPG | Full name | serum osteoprotegerin | Molecular Type | protein |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | bone metabolism regulation | ||
| Disease | Osteoporosis (OP) | Disease Subtypes | / | ||
| Organ | Bone | Test Sample / Technology Platform | Serum (ELISA, Western blot) | ||
| Pathobiological Mechanisms | As a decoy receptor for RANKL, it inhibits osteoclast differentiation and activity. The decline in estrogen levels after menopause leads to reduced OPG expression, resulting in an imbalance in bone resorption. | ||||
| Clinical Availability Status | Clinical trials in progress | ||||
| Notes and Dynamics | The diagnostic value of individual detection is limited, whereas combined detection with RANKL (OPG/RANKL ratio) improves the accuracy of postmenopausal osteoporosis risk stratification, with a ratio <0.8 indicating high risk. | ||||